Sold as Draximage Mdp-10, Draximage Mdp-25. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Technetium Tc-99m Medronate (sold as Draximage Mdp-10, Draximage Mdp-25), first approved Nov 28, 1978, with 0 new uses approved and 0 published complete response letters.
| Breast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone ScintigraphyBreast Cancer · Sohag University | — | Not yet recruiting | Aug 6, 2026 |
| Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsCastration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone · University of California, San Francisco | Phase 2 | Active, not recruiting | Jun 29, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 28, 1978 | Draximage Mdp-10, Draximage Mdp-25NDA 18035 · New formulation or manufacturer | Jubilant | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA